Vtv Therapeutics Stock News

Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items possibly impacting those stocks

vTv Therapeutics (VTVT) stock is taking off on Wednesday after entering into a funding and collaboration agreement with G42 Investments. The post vTv Therapeutics (VTVT) Stock Surges 41% on Major Inve

HIGH POINT, N.C., June 01, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $25 million investment by G42 Investments AI Holding RSC

These seven micro-cap stocks, either due to catalysts or a low valuation, could make a move to substantially higher prices. The post 7 Mighty Micro-Cap Stocks That Could Be Future Moonshots appeared f

Looking for oversold biotech stocks? These three have all seen significant drops this year despite promising catalysts for the future.

HIGH POINT, N.C., May 12, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter ended March 31, 2022, and provided an update on the prog

The FDA accepts and grants priority review to Regeneron (REGN) and Sanofi's sBLA for Dupixent to treat eosinophilic esophagitis in patients aged 12 years and older. A decision is due on Aug 3, 2022.

Gainers Sky Harbour Group Corporation (NYSE: SKYH ) shares jumped 48.4% to close at $10.09 on Friday. RISE Education Cayman Ltd (NASDAQ: REDU ) gained 39.7% to settle at $0.95. RISE Education Cayman recently entered into a definitive merger agreement with Dada Auto Inc. HOOKIPA Pharma Inc. (NASDAQ: HOOK ) surged 24% to close at $2.48. HOOKIPA Pharma recently entered into an amended and restated collaboration and license agreement with Gilead to develop immunotherapies against HIV. Universal Security Instruments, Inc. (NYSE: UUU ) jumped 23.8% to settle at $2.99. Universal Security Instruments recently said Q3 EPS results were lower year over year. Amplitude, Inc. (NASDAQ: AMPL ) gained 20.8% to close at $20.66. Amplitude recently reported Q4 earnings results and issued Q1 and FY22 sales guidance below estimates. Maris-Tech Ltd. (NASDAQ: MTEK ) climbed 20.7% to close at $2.27. Maris-Tech reported plans to co-develop video-based advanced AI systems for drones and autonomous vehicles. Cyngn Inc. (NASDAQ: CYN ) gained 20% to close at $1.74.

Here are three penny stocks to watch this week The post Best Penny Stocks to Watch This Coming Week  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Low float penny stocks to add to your watch list right now. The post Best Penny Stocks To Buy? 8 Low Float Stocks To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information

Upgrades Roth Capital upgraded the previous rating for Denbury Inc (NYSE:DEN) from Neutral to Buy. For the third quarter, Denbury had an EPS of $0.74, compared to year-ago quarter EPS of $0.05. The s

Low float penny stocks to add to your watch list right now. The post Best Penny Stocks To Buy?

The vTv Therapeutics (NASDAQ: VTVT) stock is trending today. This is why.

HIGH POINT, N.C., Jan. 13, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company committed to improving the quality of life for people with diabet

HIGH POINT, N.C., Jan. 13, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ: VTVT ), a clinical-stage biopharmaceutical company committed to improving the quality of life for people with diabetes, is sharing its updated corporate presentation highlighting its lead program TTP399, a novel oral liver-selective glucokinase activator, as a transformative treatment in the reduction of hypoglycemic episodes for the global diabetes population. Key Takeaways include: Hypoglycemia is common in people with type 1 diabetes and can occur quickly, with symptoms including sweating, nausea, coordination problems, headaches and even seizures. TTP399 may be used as a once-daily, oral adjunctive therapy in a $16B global insulin market for the reduction of hypoglycemic episodes. TTP399 has been tested in almost 600 patients to date with no evidence of diabetic ketoacidosis. vTv has worldwide rights to TTP399 with global pivotal trials anticipated in 2022. vTv is actively seeking to raise non-dilutive capital through licensing TTP399 in regions outside of North America and Europe. vTv is also actively seeking licensing deals for HPP737 and other assets. "We are excited to share our presentation highlighting the differentiation of TTP399 and the massive market opportunity it presents as an